All articles by James Mitchell Crow – Page 5
-
Feature
Reinvesting in the future
Northern Ireland-based Almac is ploughing the profits from its pharmaceutical support divisions into a range of new research ventures. James Mitchell Crow visits the company
-
Opinion
Editorial: Economic science
As the recession bites deeper, what could be in store for academe?
-
News
Hexion buys its way out of Huntsman merger
Chemistry World's pick of last year's research papers
-
News
BASF closes 80 plants as demand slumps
Temporary shutdowns and production cuts represent 25 per cent of company's total capacity
-
News
BP quits carbon capture competition
Just three consortia will now compete for UK government funding to build a CCS demonstration plant
-
News
Biodiesel from forest fungus
Patagonian fungus that converts cellulose to biodiesel could challenge theories on fossil fuel origins
-
News
Double reactor makes hydrogen and syngas
Fuel-forming reactions coupled to boost their efficiency
-
News
Interview: Pierre Brondeau
Rohm and Haas's CEO-in-waiting discusses the company's imminent takeover by Dow
-
News
Viagra variants could beat muscle fatigue
Muscular dystrophy patients' tiredness after exercise could be treated with erectile dysfunction pills.
-
News
UK chemists warn of funding crisis
Sharp drop in grant numbers hits young scientists and blue skies research
-
News
Clever catalysts promise commercial advantage
Chemical industry showcases cheaper, smarter catalysts for pharma at CPhI trade show
-
News
AkzoNobel to cut 3500 jobs
ICI's new owner aims to save a further 100 million euros by cutting costs
-
News
Two catalysts better than one
Combining transition metals with organocatalyst to make elusive molecules
-
News
Drug discovery on a chip
Affinity testing on the tiniest scale identifies a potential drug for hepatitis C